This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
NS-398
Accession Number
DB14060
Type
Small Molecule
Groups
Experimental
Description

NS-398 is a COX-2 inhibitor used in the study of the function of cyclooxygenases.

Structure
Thumb
Synonyms
  • N-(2-Cyclohexyloxy-4-nitrophenyl)methanesulfonamide
External IDs
NS 398 / NS-398 / NS398
Categories
UNII
Not Available
CAS number
123653-11-2
Weight
Average: 314.357
Monoisotopic: 314.093642386
Chemical Formula
C13H18N2O5S
InChI Key
KTDZCOWXCWUPEO-UHFFFAOYSA-N
InChI
InChI=1S/C13H18N2O5S/c1-21(18,19)14-12-8-7-10(15(16)17)9-13(12)20-11-5-3-2-4-6-11/h7-9,11,14H,2-6H2,1H3
IUPAC Name
N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide
SMILES
CS(=O)(=O)NC1=CC=C(C=C1OC1CCCCC1)[N+]([O-])=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
ACyclooxygenase 2
inhibitor
Canis lupus familiaris
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with (S)-Warfarin.
4-hydroxycoumarinThe risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with 4-hydroxycoumarin.
AbacavirNS-398 may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with Abciximab.
AcarboseNS-398 may decrease the excretion rate of Acarbose which could result in a higher serum level.
AcebutololNS-398 may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with NS-398.
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with NS-398.
AcenocoumarolThe risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with Acenocoumarol.
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
4393
BindingDB
50029593
ChEBI
73458
ChEMBL
CHEMBL7162
PharmGKB
PA166049196
HET
NS4
Wikipedia
NS-398
PDB Entries
3qmo

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0277 mg/mLALOGPS
logP3.04ALOGPS
logP1.93ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)6.81ChemAxon
pKa (Strongest Basic)-4.9ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area98.54 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity76.54 m3·mol-1ChemAxon
Polarizability31.2 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Canis lupus familiaris
Pharmacological action
Yes
Actions
Inhibitor
General Function
Not Available
Specific Function
Enzyme binding
Gene Name
PTGS2
Uniprot ID
Q8SPQ9
Uniprot Name
Cyclooxygenase 2
Molecular Weight
68974.625 Da
References
  1. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S: NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins. 1994 Jan;47(1):55-9. [PubMed:8140262]
  2. Yao M, Lam EC, Kelly CR, Zhou W, Wolfe MM: Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. Br J Cancer. 2004 Feb 9;90(3):712-9. doi: 10.1038/sj.bjc.6601489. [PubMed:14760389]
  3. Zhang R, Liu Z, Zhang H, Zhang Y, Lin D: The COX-2-Selective Antagonist (NS-398) Inhibits Choroidal Neovascularization and Subretinal Fibrosis. PLoS One. 2016 Jan 13;11(1):e0146808. doi: 10.1371/journal.pone.0146808. eCollection 2016. [PubMed:26760305]
  4. Mastrangelo D, Wisard M, Rohner S, Leisinger H, Iselin CE: Diclofenac and NS-398, a selective cyclooxygenase-2 inhibitor, decrease agonist-induced contractions of the pig isolated ureter. Urol Res. 2000 Dec;28(6):376-82. [PubMed:11221916]

Drug created on June 14, 2018 13:37 / Updated on November 02, 2018 07:49